Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Daymond John from "Shark Tank" made a surprise appearance at a major health tech conference—and remarked on the number of ...

Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Hims & Hers Health ( HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Healthcare CIOs are zeroing in on the following areas to fuel innovation and upgrade their existing solutions.

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, ...